Drug Index


Mechanism :

It is an Interleukin-5 (IL-5) Inhibitor available as a monoclonal antibody and is used as immunotherapy. 

Indication :

  • Indicated for add-on maintenance treatment of severe asthma in patients with an eosinophilic phenotype aged ≥12 years

Contraindications :

  • It is to be avoided in patients with a history of hypersensitivity to benralizumab. Use with caution in patients with hamster protein hypersensitivity, as the drug is produced in Chinese hamster ovary cells.
  • Benralizumab should not be used to treat acute bronchospasm or status asthmaticus.
  • Benralizumab reduces the production and survival of eosinophils, which may be involved in the immunological response to some helminth infections. Hence treat worm infestation first before starting benralizumab. 

Dosing :

It is available as a injection (1 mL = 30 mg) to be given subcutaneously.
<12 years:
Safety and efficacy not established.
≥12 years:
30 mg SC every 4 weeks for the first 3 doses, and then to be given every 8 weeks(Max dose: 30 mg/dose).

Adverse Effect :

Headache, pharyngitis, fever, hypersensitivity reactions

Interaction :

There are no drug interactions associated with Benralizumab. 
03/21/2024 00:21:45 Benralizumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0